BiotechTube

dirucotide + Placebo

Phase 2/3Completed
1 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Secondary Progressive Multiple Sclerosis

Conditions

Secondary Progressive Multiple Sclerosis

Trial Timeline

Dec 1, 2004 → May 1, 2009

NCT ID
NCT00869726

About dirucotide + Placebo

dirucotide + Placebo is a phase 2/3 stage product being developed by Eli Lilly for Secondary Progressive Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00869726. Target conditions include Secondary Progressive Multiple Sclerosis.

What happened to similar drugs?

13 of 20 similar drugs in Secondary Progressive Multiple Sclerosis were approved

Approved (13) Terminated (0) Active (7)
✅Cinacalcet HClKyowa KirinApproved
✅Paricalcitol + CalcifediolAbbVieApproved
✅Paricalcitol + Darbepoetin alfaAbbVieApproved
✅RanibizumabNovartisApproved
✅BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
✅RanibizumabNovartisApproved
✅Sensipar® + Vitamin DAmgenApproved

Hype Score Breakdown

Clinical
15
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT00869986Phase 2/3Completed
NCT00869726Phase 2/3Completed

Competing Products

20 competing products in Secondary Progressive Multiple Sclerosis

See all competitors
ProductCompanyStageHype Score
ASP7991 + Cinacalcet + PlaceboAstellas PharmaPhase 2
35
FycompaEisaiPre-clinical
26
FycompaEisaiPre-clinical
26
KHK7580 + KRN1493Kyowa KirinPhase 2/3
38
KHK7580Kyowa KirinPhase 1
29
KHK7580Kyowa KirinPhase 3
40
KHK7580Kyowa KirinPhase 3
40
Cinacalcet HClKyowa KirinApproved
43
KHK7580 + Cinacalcet HydrochlorideKyowa KirinPhase 3
40
Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493Kyowa KirinPhase 2
35
dirucotideEli LillyPhase 2/3
30
Paricalcitol + CalcitriolAbbViePre-clinical
18
paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placeboAbbViePhase 3
40
Paricalcitol + CalcifediolAbbVieApproved
43
Paricalcitol + Darbepoetin alfaAbbVieApproved
43
Birabresib Dose 20 mgMerckPhase 1
21
Remibrutinib (blinded) + Placebo + Remibrutinib (Open label)NovartisPhase 3
47
RanibizumabNovartisApproved
43
BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273NovartisApproved
43
Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDTNovartisPhase 3
40